Health Condition 1: C539- Malignant neoplasm of cervix uteri, unspecified
Conditions
Interventions
Intervention1: Induction chemotherapy followed by chemoradiation: Induction chemotherapy consist of paclitaxel@ 175mg/square meter of body surface area intravenously day 1 along with carboplatin dosed
Sponsors
institute of Medical Sciences Banaras Hindu University
Eligibility
Inclusion criteria
Inclusion criteria: Histologically proven cases of cervical cancer. FIGO 2018 stages IB3 to IVA. ECOG performance status 0-2 Adequate hematological, hepatic and renal function. (Hb more than equal to 10,TLC more than equal to 4000, Platelet count more than 100000, Serum creatinine less than or equal to 1.4, Creatinine clearance more than or equal to 60.
Exclusion criteria
Exclusion criteria: pregnant or lactating females. history of previous cancer. history of prior radiation to pelvis synchronous malignancy.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Locoregional Control Acute toxicityTimepoint: For acute toxicity:Weekly during chemoradiation, upto 3 months of completion of chemoradiation. For Locoregional control : 3 months and 6 months | — |
Secondary
| Measure | Time frame |
|---|---|
| Disease free survivalTimepoint: 3 months 6 months;Overall SurvivalTimepoint: 3 months 6 months;Late adverse eventsTimepoint: 3 months 6 months;Quality of LifeTimepoint: Before start of chemoradiation After completion of chemoradiation | — |
Countries
India
Contacts
Public ContactDr Ritusha Mishra
IMS,BHU
Outcome results
None listed